Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Senior VP and General Counsel | January 25, 2017 | January 27, 2017 |
| MyoKardia, Inc.MYOK · Entity 145206 | General Counsel | February 14, 2020 | February 19, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date January 25, 2017 · Filed January 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.94 · Expires 2027-01-24 | Direct | 84,000 |
Reported balance
After 2017-01-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-25 · Grant · Acquired 84,000 · Balance 84,000 F1: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
MyoKardia, Inc.
Report date February 14, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.40 · Expires 2030-02-13 | Direct | 31,079 |
Reported balance
After 2020-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-14 · Grant · Acquired 31,079 · Balance 31,079 F1: The shares underlying the option vest in 48 equal monthly installments from January 1, 2020, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,034 |
Reported balance
After 2020-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-14 · Grant · Acquired 10,034 · Balance 10,034 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option vest in 48 equal monthly installments from January 1, 2020, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2020 Filed Feb 19, 2020 20:44 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantRestricted Stock Units · Derivative | 10,034 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-005190 · doc4.xml · derivative · entry 2 LADD CYNTHIA J · CIK 0001217596 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,034 Underlying: Common Stock · 10,034 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 20:44 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 31,079 | $0.00 Strike: $70.40 | $0.00 |
DisclosureSEC source: 0000899243-20-005190 · doc4.xml · derivative · entry 1 LADD CYNTHIA J · CIK 0001217596 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,079 Underlying: Common Stock · 31,079 shares Expires 2030-02-13 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2020, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| January 06, 2020 Filed Jan 7, 2020 19:36 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 1,849 | $68.45 | $126,566.08 |
DisclosureSEC source: 0000899243-20-000789 · doc4.xml · nonDerivative · entry 1 LADD CYNTHIA J · CIK 0001217596 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,851 F1 · kind: Shares sold to cover withholding taxes in connection with vesting of Restricted Stock Units reported on Form 4 filed by the Reporting Person on January 3, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $68.35 to $68.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 20:18 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionRestricted Stock Units · Derivative | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-000386 · doc4.xml · derivative · entry 2 LADD CYNTHIA J · CIK 0001217596 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 4,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 20:18 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 4,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-000386 · doc4.xml · nonDerivative · entry 1 LADD CYNTHIA J · CIK 0001217596 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 16:32 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantRestricted Stock Units · Derivative | 18,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-003300 · doc4.xml · derivative · entry 2 LADD CYNTHIA J · CIK 0001217596 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,800 Underlying: Common Stock · 18,800 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 16:32 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 55,100 | $0.00 Strike: $40.11 | $0.00 |
DisclosureSEC source: 0000899243-19-003300 · doc4.xml · derivative · entry 1 LADD CYNTHIA J · CIK 0001217596 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,100 Underlying: Common Stock · 55,100 shares Expires 2029-02-07 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2019, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 18:02 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $54.05 | $0.00 |
DisclosureSEC source: 0000899243-18-002691 · doc4.xml · derivative · entry 1 LADD CYNTHIA J · CIK 0001217596 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2028-01-31 F1 · derivative.exercise_date: 1/4th of the underlying shares shall vest on January 16, 2019; thereafter, the shares subject to this option shall vest and become exercisable in 36 equal monthly installments with the first installment on February 16, 2019, such that this option is fully exercisable on January 16, 2022. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan). Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 13:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 84,000 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001140361-17-003157 · doc1.xml · derivative · entry 1 LADD CYNTHIA J · CIK 0001217596 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,000 Underlying: Common Stock · 84,000 shares Expires 2027-01-24 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.